IGF1R and neoplasm: have subsequently demonstrated that co-targeting PD-1 and IGF1R resulted in a significant decrease in the number of T-regs and an increase in intratumoral cytotoxic CD8+ T cells leading to an improvement of anti-tumor efficacy in an in vivo mouse model of lung cancer (55).